To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2009-05-31

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine whether Al38583 Ophthalmic Solution is safe and effective in reducing tear eosinophil levels at 5-8 hours after Conjunctival Allergen Challenge (CAC).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Compare Dose Regimens of AllerT, in Adults With Allergic Rhino-Conjunctivitis to Birch Pollen Studied in EEC

NCT02271009

Allergic Rhino-Conjunctivitis

COMPLETED PHASE2

Ocular Allergy Treatment Practical Impact Trial

NCT01808768

Allergic Conjunctivitis Rhinoconjunctivitis

UNKNOWN PHASE4

Safety and Efficacy of AL-53817 Nasal Spray Solution

NCT01454505

Nasal Allergies Allergies

COMPLETED PHASE1

Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)

NCT00818805

Allergic Conjunctivitis

COMPLETED PHASE4

Assessment of Alcon's Ocular Image Quantification System

NCT01282138

Allergic Conjunctivitis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergic Conjunctivitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

AL38583 Ophthalmic Solution

Intervention Type DRUG

Topical ophthalmic

2

Group Type ACTIVE_COMPARATOR

Maxidex

Intervention Type DRUG

Topical ophthalmic

3

Group Type PLACEBO_COMPARATOR

Vehicle

Intervention Type DRUG

AL38583 Vehicle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AL38583 Ophthalmic Solution

Topical ophthalmic

Intervention Type DRUG

Maxidex

Topical ophthalmic

Intervention Type DRUG

Vehicle

AL38583 Vehicle

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a positive bilateral CAC reaction (\>2 itching and \> conjunctival redness) to cat hair, cat dander, dust mites, cockroaches and/or dog dander within 10 minutes of instillation of the last titration of allergen at Visit 1